← Back to Search

GLP-1 Receptor Agonist

Tirzepatide - Test for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 36 days postdose
Awards & highlights

Study Summary

This trial evaluates the effectiveness, safety and tolerability of tirzepatide. Participants will be monitored over 14 weeks, and side effects recorded.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 36 days postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 36 days postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Tirzepatide
PK: Area Under the Plasma Concentration Versus Time Curve from Zero to Time t (AUC[0-t]) of Tirzepatide
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Tirzepatide - TestExperimental Treatment2 Interventions
A single dose of tirzepatide administered by subcutaneous (SC) injection via a test device (test formulation)
Group II: Tirzepatide - ReferenceActive Control2 Interventions
A single dose of tirzepatide administered by SC injection via a reference device (reference formulation)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tirzepatide
2019
Completed Phase 3
~5560
Test
2021
Completed Phase 3
~1700

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,624 Previous Clinical Trials
3,216,856 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,349 Previous Clinical Trials
415,615 Total Patients Enrolled
~30 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top